The DOI matches its Crossref record; 148 of the 148 references it cites were found in a registry or an index.
Alcohol-associated liver disease—Global epidemiology
Open accessAbstract
Alcohol-associated liver disease (ALD), as highlighted in this narrative review, is a major public health concern, increasingly impacting global disease burden and premature mortality. In 2019, ALD accounted for the loss of 11 million life-years worldwide. The rising number of deaths and disability-adjusted life-years attributed to ALD, particularly pronounced in the United States, are alarming. Projections suggest that the economic impact of ALD, as seen in the United States, could potentially double by 2040. ALD is increasingly prevalent among younger adults (20-45 y) and has become the leading cause of liver transplantation in both United States and Europe. During the COVID-19 pandemic, the existing trend was further amplified as high-risk drinking patterns coincided with a rise in hospital admissions for alcohol-associated hepatitis and increased ALD-related mortality. The prevalence of ALD is estimated at 3.5% in the general population, 26.0% among hazardous drinkers, and 55.1% among those with alcohol use disorders. Alarmingly, 5-year mortality rates for patients with ALD exceed 50%, with even higher rates in more advanced disease stages. Methodological challenges, such as underreporting, diagnostic difficulties, and variability in registry data quality, complicate the accurate assessment of the impact of ALD. Additionally, the contribution of alcohol to the progression of other liver diseases is often under acknowledged in health care registries, leading to a significant underestimation of its broader implications for liver health. Addressing the growing ALD concern requires robust public health initiatives, heightened awareness, refined diagnostic techniques, and comprehensive epidemiological studies. These measures are vital to tackle the increasing prevalence of ALD and mitigate its extensive impact on individuals and health care systems.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160 · cited 1×
“[104] Etiologies causing liver cancer can vary significantly by region.”
Vos, T., Lim, S. S., Abbafati, C., Abbas, K. M., Abbasi, M., Abbasifard, M., Abbasi-Kangevari, M., Abbastabar, H., Abd-Allah, F., Abdelalim, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30925-9 · Cited by 19,358
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476 · cited 1×
“[26] Patients with SLD who report alcohol intake of 20 – 50 grams daily for women or 30 – 60 grams for men and present with at least 1 cardiometabolic risk factor are now classified as having combined metabolic dysfunction – associated and alcohol-associated liver disease (Figure 1).”
Self-citationGlobal Burden of Disease Liver Cancer Collaboration, Akinyemiju, T., Abera, S., Ahmed, M., Alam, N., Alemayohu, M. A., Allen, C., Al-Raddadi, R., Alvis-Guzman, N., Amoako, Y., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3055 · Cited by 1,987
Sepanlou, S. G., Safiri, S., Bisignano, C., Ikuta, K. S., Merat, S., Saberifiroozi, M., Poustchi, H., Tsoi, D., Colombara, D. V., Abdoli, A., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30349-8 · Cited by 1,714
Grant, B. F., Chou, S. P., Saha, T. D., Pickering, R. P., Kerridge, B. T., Ruan, W. J., Huang, B., Jung, J., Zhang, H., Fan, A., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.2161 · Cited by 1,362 · cited 1×
“[95,96] A comprehensive study encompassing 27 countries reported an 8.6% mean lifetime prevalence of alcohol use disorders, ranging from 2.4% in the Eastern Mediterranean to 13.7% in the Western Pacific region.”
InfluentialLeclercq, S., Matamoros, S., Cani, P. D., Neyrinck, A. M., Jamar, F., Stärkel, P., Windey, K., Tremaroli, V., Bäckhed, F., Verbeke, K., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1415174111 · Cited by 972
EASL Clinical Practice Guidelines: Management of alcohol-related liver disease
Thursz, M., Gual, A., Lackner, C., Mathurin, P., Moreno, C., Spahr, L., Sterneck, M., & Cortez-Pinto, H. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.018 · Cited by 943
Self-citation
Research works printed but not linked: 1
- Tu, 2023, Decreased mortality in patients with severe alcohol-associated hepatitis (sah) Treated With Corticosteroids During the COVID pandemic, Hepatology, 78, S1
Cited by
Maccioni, L., Guan, Y., Kim, M., Parra, M. A., Peiffer, B., Fu, Y., Wang, Y., Lin, Y.-H., Mackowiak, B., Feng, D., et al. (2025) · Gut · doi:10.1136/gutjnl-2024-334412 · Cited by 21
Macrophage heterogeneity in liver fibrosis
Wang, W., Li, S., Liu, Y., Ding, X., Yang, Y., Chen, S., Cao, J., Tacke, F., Dong, W., & Lan, T. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1639455 · Cited by 8
Metadata
- Authors
- Åberg, F., Jiang, Z. G., Cortez-Pinto, H., & Männistö, V.
- Affiliations
- University of Helsinki (FI)
- Beth Israel Deaconess Medical Center (US)
- Clínica Universitária de Gastrenterologia, Faculdade de Medicina, Universidade de Lisboa, Portugal
- University of Eastern Finland (FI)
- Corresponding author
- Åberg, Fredrik
- Venue
- Hepatology
- Published
- 2024-04-19
- Volume
- 80
- Issue
- 6
- Pages
- 1307-1322
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W4394951455
- Cited by
- 163
- References
- 148
- Citations by year
- 2026: 94 · 2025: 61 · 2024: 8
- FWCI
- 12.14
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Työväentutkimus Vuosikirja (submittedVersion, other-oa)
- Funders
- National Institute on Alcohol Abuse and Alcoholism (R01AA030770)
- National Institute of Diabetes and Digestive and Kidney Diseases (K08DK115883, L30 DK118655)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Keywords
- alcoholic liver disease, global epidemiology, disease burden, premature mortality, disability-adjusted life years, economic impact, liver transplantation, alcoholic hepatitis, COVID-19 pandemic, hazardous drinking, alcoholism, underreporting, diagnostic challenges, registry data quality, young adults
- MeSH terms
- Global Burden of Disease, COVID-19, SARS-CoV-2, Adult, Aged, Aged, 80 and over, Female, Humans, Liver Diseases, Alcoholic, Male, Middle Aged, Global Health, Prevalence, Liver Transplantation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Alcohol-associated liver disease—Global epidemiology. https://app.cochat.ai/papers/10.1097/hep.0000000000000899
- The paper
- Åberg, F., Jiang, Z. G., Cortez-Pinto, H., & Männistö, V. (2024). Alcohol-associated liver disease—Global epidemiology. Hepatology. https://doi.org/10.1097/hep.0000000000000899
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.